CDH2 and breast carcinoma: Previously, we demonstrated that F3 had anti-metastatic activity in breast cancer by reducing the expression of N-cadherin, vimentin, MMP-9, MUC1, Twist, and VEGF, while increasing the expression of E-cadherin [28].